Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT07742657

A Clinical Trial to Evaluate the Effects of Super Liver Liquid Drops on Gut Health, Digestive Comfort, and Daily Energy Levels

This is a decentralized (fully virtual), single-group, open-label, prospective clinical trial evaluating the effects of Super Liver Liquid Drops, a liquid botanical dietary supplement, on gut health, digestive comfort, energy levels, and overall well-being over 12 weeks. All 35 enrolled participants will self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each) in the morning with breakfast for the full 12-week intervention period.

Participants will complete validated questionnaires and self-reported assessments at Baseline, Week 2, Week 4, Week 8, and Week 12 via the Citruslabs study platform. All study activities will be conducted remotely.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Gastrointestinal Symptoms Bad Breath Behavior Behavioral Symptoms Bloating Brain Fog Digestive Discomfort Dyssomnias Facial Puffiness Fatigue Halitosis Low Energy Levels Mental Disorders Mental Fatigue Mood Instability Nervous System Diseases Pathological Conditions, Signs and Symptoms Signs and Symptoms Signs and Symptoms, Digestive Skin Clarity Sleep Disorders, Intrinsic Sleep Initiation and Maintenance Disorders Sleep Quality Sleep Wake Disorders

Age range

30 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Citruslabs

Las Vegas, Nevada, 89118, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Be male or female.
  • Be aged 30-65 years (inclusive) at the time of enrollment.
  • Over the past four weeks, has had concerns regarding low energy levels and at least two of the following: Bloating, Digestion, Irregular Bowel movements, Brain fog.
  • Anyone who is generally healthy - does not live with any uncontrolled chronic disease.
  • Willing and able to follow the study protocol as described.
  • Willing to maintain their current diet, exercise routine, and sleep patterns, for the duration of the trial.
  • If taking other over-the-counter supplements or herbal remedies is willing to maintain this routine without introducing any other new products for the study duration.
  • Resides in the United States.
  • Willing to follow the study protocol as described.

Exclusion criteria

  • Known allergy or sensitivity to any of the study product ingredients (milk thistle, dandelion, yellow dock, turmeric, ginger, chicory/inulin, berberine).
  • Known history of severe digestive disorders like acid reflux, Irritable Bowel Syndrome (IBS), Irritable Bowel Disease (IBD), Crohn's disease, or gastrointestinal tract surgeries.
  • Known history of gallbladder disease or bile duct obstruction.
  • Has a chronic health condition that could impact participation in this study, such as oncological or psychiatric disorders.
  • Has a planned surgery in the next 12 weeks.
  • Currently pregnant, breastfeeding, or planning to become pregnant during the study period.
  • Known history of substance abuse.
  • Currently, or was in the past 3 months, a smoker.
  • Currently participating in or planning to participate in another research study during the study period.

Treatment and study plan

Super Liver

Dietary Supplement

All 35 enrolled participants self-administer 2 mL of Super Liver Liquid Drops daily (2 droppers filled to 1 mL each), taken in the morning with breakfast, for 12 consecutive weeks.

Primary outcomes

  1. Change in Gastrointestinal Symptom Rating Scale (GSRS)

    Time frame: Baseline to Week 12

    Change from baseline to Week 12 in gastrointestinal symptom severity as assessed by the Gastrointestinal Symptom Rating Scale (GSRS). Higher scores indicate greater gastrointestinal symptom severity.

Secondary outcomes

  1. Change in Self-Reported Energy Level Score

    Time frame: Baseline to Week 12

    Change from baseline to Week 12 in participant-reported energy level, as assessed using the study questionnaire.

  2. Change in Self-Reported Brain Fog Score

    Time frame: Baseline to Week 12

    Change from baseline to Week 12 in participant-reported brain fog, as assessed using the study questionnaire.

  3. Change in Self-Reported Mood Stability Score

    Time frame: Baseline to Week 12

    Change from baseline to Week 12 in participant-reported mood stability, as assessed using the study questionnaire.

  4. Change in Self-Reported Sleep Quality Score

    Time frame: Baseline to Week 12

    Change from baseline to Week 12 in participant-reported sleep quality, as assessed using the study questionnaire.

  5. Change in Self-Reported Skin Clarity Score

    Time frame: Baseline to Week 12

    Change from baseline to Week 12 in participant-reported skin clarity, as assessed using the study questionnaire.

  6. Incidence and Severity of Treatment-Emergent Adverse Events (TEAEs)

    Time frame: Continuous monitoring over 12 weeks

    Incidence, severity, and relationship to study product of treatment-emergent adverse events occurring from the first dose of study product through the end of the 12-week study period.

Sponsors and collaborators

Lead sponsor

SuperBonsai Inc.

Industry

Collaborators

  • Citruslabs

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Aug 3, 2026
Registry last updated
Aug 3, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.